ATE375171T1 - Heilmittel für krebs - Google Patents

Heilmittel für krebs

Info

Publication number
ATE375171T1
ATE375171T1 AT01945613T AT01945613T ATE375171T1 AT E375171 T1 ATE375171 T1 AT E375171T1 AT 01945613 T AT01945613 T AT 01945613T AT 01945613 T AT01945613 T AT 01945613T AT E375171 T1 ATE375171 T1 AT E375171T1
Authority
AT
Austria
Prior art keywords
cancer
cure
useful
preventing
type
Prior art date
Application number
AT01945613T
Other languages
English (en)
Inventor
Kohji Hanasaki
Minoru Ikeda
Takashi Ono
Original Assignee
Anthera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthera Pharmaceuticals Inc filed Critical Anthera Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE375171T1 publication Critical patent/ATE375171T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01945613T 2000-06-29 2001-06-27 Heilmittel für krebs ATE375171T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000195434 2000-06-29

Publications (1)

Publication Number Publication Date
ATE375171T1 true ATE375171T1 (de) 2007-10-15

Family

ID=18694096

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01945613T ATE375171T1 (de) 2000-06-29 2001-06-27 Heilmittel für krebs

Country Status (8)

Country Link
US (1) US20040077651A1 (de)
EP (1) EP1300159B1 (de)
AT (1) ATE375171T1 (de)
AU (1) AU2001267824A1 (de)
DE (1) DE60130891T2 (de)
ES (1) ES2294003T3 (de)
TW (1) TW583000B (de)
WO (1) WO2002000255A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS282602A0 (en) * 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
AU2005297800B2 (en) 2004-10-29 2011-02-03 Zeria Pharmaceutical Co., Ltd. Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof
CN101528740B (zh) * 2006-09-29 2012-09-19 株式会社绿十字 作为大麻素cb1受体拮抗剂的杂芳基-吡唑衍生物
EP2337801A4 (de) 2008-10-06 2012-07-25 Minerva Biotechnologies Corp Muc1*-antikörper
MY198422A (en) 2009-04-29 2023-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
US5478857A (en) * 1993-12-23 1995-12-26 Eli Lilly And Company Use of PLA2 inhibitors as treatment for alzheimer's disease
PE18696A1 (es) * 1994-04-01 1996-05-30 Lilly Co Eli 1H-INDOL-3-GLIOXILAMIDA INHIBIDORA DE sPLA2
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
US5935860A (en) * 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
WO1999024033A1 (en) * 1997-11-12 1999-05-20 Shionogi & Co., Ltd. Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
JP2001522884A (ja) * 1997-11-14 2001-11-20 イーライ・リリー・アンド・カンパニー アルツハイマー病の処置方法
JP3256513B2 (ja) * 1998-02-11 2002-02-12 ファイザー製薬株式会社 ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤
US6028116A (en) * 1998-04-03 2000-02-22 Cell Pathways, Inc. Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
EP1135141A4 (de) * 1998-11-12 2003-03-05 Analytica Ltd Phospholipase inhibitoren zur behandlung von krebs
WO2001026653A1 (fr) * 1999-10-15 2001-04-19 Shionogi & Co., Ltd. Inhibiteurs spla2 du type v et/ou du type x

Also Published As

Publication number Publication date
TW583000B (en) 2004-04-11
ES2294003T3 (es) 2008-04-01
US20040077651A1 (en) 2004-04-22
DE60130891D1 (de) 2007-11-22
AU2001267824A1 (en) 2002-01-08
EP1300159A4 (de) 2005-08-24
WO2002000255A1 (fr) 2002-01-03
EP1300159A1 (de) 2003-04-09
EP1300159B1 (de) 2007-10-10
DE60130891T2 (de) 2008-07-17

Similar Documents

Publication Publication Date Title
NO20032229D0 (no) Fremgangsmåter for behandling av p38kinase-assosierte tilstander og pyrrolotriazin forbindelser nyttige som kinase inhibitorer
ITTO20021024A1 (it) Trattamento di superficie per componenti ferrosi.
DK0912535T3 (da) Konjugater af cis-docosahexaensyre og paclitaxel
CY1105649T1 (el) Παραγωγο πυριμιδιν -4- ονης ως αναστολεας της ldl-pla2
DE60229591D1 (de) Trägerplattenvorrichtung
NO20015650D0 (no) Pyrrolotriazin-inhibitorer for kinaser
NO20021526D0 (no) Anordning for kloakkbehandling
DE60139096D1 (de) Optischer Kettenverstärker und Verfahren zur optischen Kettenverstärkung
DE50113389D1 (de) Lichtquelle
DE60229959D1 (de) Kombinationstherapie zur behandlung von krebs
DE69913928D1 (de) Mehrwellenlängen-Quelle
DE60126205D1 (de) Oberflächenemittierender Laser zur Ausstrahlung mehrerer Wellenlängen und zugehöriges Herstellungsverfahren
CY1110202T1 (el) Νεοι συνδυασμοι ενος αντι εμετικου παραγοντα και ενος αναστολεα της εγκεφαλινασης
SE0301650D0 (sv) Novel compounds
ATE375171T1 (de) Heilmittel für krebs
BR0109512A (pt) Imidazopiridinas tricìclicas
DE69907803D1 (de) Laserbehandlungsgerät
NO20025399L (no) Fosfat transport inhibitorer
ATE405834T1 (de) Bindungsoberfläche
DE60213495D1 (de) Streifenförmige Quellenanordnung zur intravaskulären Radiotherapie
DE60111207D1 (de) Stabilisierte strahlungsquelle
DE60042606D1 (de) Anti-angiogener zellulärer wirkstoff zur krebsbehanldung
BR0214799B1 (pt) instalação flutuante para tratamento de hidrocarbonetos.
DE69811963T2 (de) Laseranordnung zum Pumpen von optischen Verstärkern
DE60103725D1 (de) Laserquelle

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties